Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong ...

Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection.  Wegovy (semaglutide) is currently approved in ...

Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...

And one of them is pharmaceutical giant Pfizer ( PFE 0.04%). Now, with a major step along the path to entering this ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show a benefit over a placebo against Alzheimer's disease.

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

LONDON/COPENHAGEN, Oct 24 (Reuters) - A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, rattling investors despite calls for ...

Novo Nordisk Chairman Helge Lund, along with several other board members, will be leaving their positions following a disagreement with the company's largest shareholder, the Novo Nordisk Foundation.